申请人:Gutman Arie
公开号:US20050049302A1
公开(公告)日:2005-03-03
The present invention provides, according to an aspect thereof, a novel process for the preparation of dronedarone [1] and pharmaceutically acceptable salts thereof. According to a preferred embodiment, the process comprises N-acetylating of p-anisidine or p-phenetidine with acetic anhydride, reacting of the obtained N-(4-alkoxyphenyl)acetamide with 2-bromohexanoyl chloride or bromide in the presence of aluminum chloride or bromide to obtain N-[3-(2-bromohexanoyl)-4-hydroxyphenyl]acetamide [6a], converting the compound [6a] into 2-butyl-5-benzofuranamine hydrochloride [12a] and subsequently converting [12a] into [1] or pharmaceutically acceptable salts thereof. In accordance with another aspect of this invention, there are provided novel intermediates, inter alia the novel compounds [6a] and [12a]. The novel intermediates of the present invention are stable, solid compounds, obtainable in high yields, which can be easily purified by crystallization and stored for long periods of time.
本发明提供了一种制备多吡咯酮[1]及其药学上可接受的盐的新工艺。根据一种优选实施方式,该工艺包括用乙酸酐对对甲氨基苯或对苯乙胺进行N-乙酰化,将得到的N-(4-烷氧基苯基)乙酰胺与2-溴已酰氯或溴在铝氯化物或溴化铝的存在下反应,得到N-[3-(2-溴已酰)-4-羟基苯基]乙酰胺[6a],将化合物[6a]转化为2-丁基-5-苯并呋喃胺盐酸盐[12a],随后将[12a]转化为[1]或其药学上可接受的盐。根据本发明的另一方面,还提供了新的中间体,其中包括新的化合物[6a]和[12a]。本发明的新中间体是稳定的固体化合物,可以高产率地得到,并且可以通过结晶轻松纯化并长时间储存。